CA3056726A1 - Tricyclic compounds for use in treatment of proliferative disorders - Google Patents

Tricyclic compounds for use in treatment of proliferative disorders Download PDF

Info

Publication number
CA3056726A1
CA3056726A1 CA3056726A CA3056726A CA3056726A1 CA 3056726 A1 CA3056726 A1 CA 3056726A1 CA 3056726 A CA3056726 A CA 3056726A CA 3056726 A CA3056726 A CA 3056726A CA 3056726 A1 CA3056726 A1 CA 3056726A1
Authority
CA
Canada
Prior art keywords
alkyl
pyrido
solvate
hydrate
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3056726A
Other languages
English (en)
French (fr)
Inventor
Andrew Morley
Rebecca Miller
Nicholas La Thangue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonaut Therapeutics Ltd
Original Assignee
Argonaut Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argonaut Therapeutics Ltd filed Critical Argonaut Therapeutics Ltd
Publication of CA3056726A1 publication Critical patent/CA3056726A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3056726A 2017-03-17 2018-03-16 Tricyclic compounds for use in treatment of proliferative disorders Pending CA3056726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704325.8A GB201704325D0 (en) 2017-03-17 2017-03-17 Compounds
GB1704325.8 2017-03-17
PCT/EP2018/056675 WO2018167276A1 (en) 2017-03-17 2018-03-16 Tricyclic compounds for use in treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
CA3056726A1 true CA3056726A1 (en) 2018-09-20

Family

ID=58688220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3056726A Pending CA3056726A1 (en) 2017-03-17 2018-03-16 Tricyclic compounds for use in treatment of proliferative disorders

Country Status (9)

Country Link
US (1) US11274098B2 (https=)
EP (1) EP3596073B1 (https=)
JP (1) JP7308765B2 (https=)
KR (1) KR102604942B1 (https=)
CN (1) CN110621675B (https=)
CA (1) CA3056726A1 (https=)
ES (1) ES2925115T3 (https=)
GB (1) GB201704325D0 (https=)
WO (1) WO2018167276A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
KR102278691B1 (ko) * 2019-08-09 2021-07-16 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체
KR102282712B1 (ko) * 2019-08-09 2021-07-27 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
WO2021029450A1 (ko) * 2019-08-09 2021-02-18 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
JP7609857B2 (ja) 2019-10-02 2025-01-07 エスケー バイオファーマスティカルズ カンパニー リミテッド 二環式化合物及びその使用
CN111454260B (zh) * 2020-05-25 2023-02-28 贵州大学 一类含异丙醇胺亚结构的1，2，3，4-四氢-β-咔啉类化合物及其制备方法和应用
CN111892593B (zh) * 2020-08-19 2021-11-16 南通大学 一种8-甲氧基-5H-吡啶并[4,3-b]吲哚及其合成方法
JP2024508235A (ja) * 2021-02-04 2024-02-26 アムジエン・インコーポレーテツド 三環－アミド－二環ｐｒｍｔ５阻害剤
CN113105517B (zh) * 2021-04-10 2022-03-01 台州仙琚药业有限公司 雄甾-1,4,9-三烯-3,17-二酮的合成方法
GB202108383D0 (en) * 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用
CN117088891A (zh) * 2023-07-13 2023-11-21 浙江大学 含四氢苯并[4,5]呋喃[2,3-c]吡啶类羟肟酸化合物及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) * 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
US3687961A (en) * 1971-05-03 1972-08-29 Abbott Lab 8-fluoro-2-{8 3-(4-fluorophenylanilinopropyl{9 -gamma-carboline
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
DE2854014A1 (de) * 1978-12-14 1980-07-03 Troponwerke Gmbh & Co Kg 7,8,9,10-tetrahydrothieno eckige klammer auf 3,2-e eckige klammer zu pyrido eckige klammer auf 4,3-b eckige klammer zu indole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4719211A (en) 1984-05-01 1988-01-12 American Home Products Corporation 2,3,4,9-tetrahydro-2-heteroarylalkyl-1H-pyrido(3,4-B)indoles having antihypertensive properties
SU1248223A1 (ru) * 1985-01-07 1995-09-20 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений ДИГИДРОХЛОРИД 2-(3-ИЗОПРОПИЛАМИНО-2-ГИДРОКСИПРОПИЛ)-1,2,3,4-ТЕТРАГИДРО- β -КАРБОЛИНА, ОБЛАДАЮЩИЙ АНТИАЛКОГОЛЬНЫМ И ПСИХОТРОПНЫМ ДЕЙСТВИЕМ
US4663456A (en) * 1985-09-16 1987-05-05 American Home Products Corporation 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA52681C2 (uk) 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP0905136A1 (en) 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
CA2593266A1 (en) 2005-01-03 2006-07-13 Universita Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2010080253A1 (en) 2008-12-18 2010-07-15 Merck Patent Gmbh Tricyclic azaindoles
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2898040A1 (en) 2013-01-14 2014-07-17 Ent Associates Of Los Alamos, Llc Honey nasal rinse
ES2786052T3 (es) 2013-04-23 2020-10-08 Esteve Pharmaceuticals Sa Compuestos de pirazino[1,2-a]indol, su preparación y su uso en medicamentos
EP3013824B8 (en) 2013-06-28 2018-11-21 Alzprotect Carboline compounds usable in the treatment of neurodegenerative diseases
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
JP2017519737A (ja) 2014-05-26 2017-07-20 バイエル・ファルマ・アクティエンゲゼルシャフト 置換テトラヒドロピリドチエノピリミジン
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3596073A1 (en) 2020-01-22
CN110621675B (zh) 2023-09-19
CN110621675A (zh) 2019-12-27
KR102604942B1 (ko) 2023-11-21
WO2018167276A1 (en) 2018-09-20
JP2020510092A (ja) 2020-04-02
GB201704325D0 (en) 2017-05-03
US20200325132A1 (en) 2020-10-15
EP3596073B1 (en) 2022-05-11
US11274098B2 (en) 2022-03-15
KR20190129071A (ko) 2019-11-19
ES2925115T3 (es) 2022-10-13
JP7308765B2 (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
US11274098B2 (en) Tricyclic compounds for use in treatment of proliferative disorders
KR102616970B1 (ko) Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물
ES2975661T3 (es) Inhibidores de BCL6 derivados de la 2-quinolona
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
US20250236624A1 (en) Heterocyclic Compounds as RET Kinase Inhibitors
ES2926641T3 (es) Derivados de N2-fenil-pirido[3,4-d]pirimidin-2,8-diamina y su uso como inhibidores de MPS1
KR20250153866A (ko) Dna 중합효소 세타 억제제
ES2877140T3 (es) Derivados de pirimidinona como inhibidores de Cdc7
US20230045929A1 (en) Isoquinoline derivatives as sik2 inhibitors
ES2845048T3 (es) Preparación y usos de derivados de pirimidinona
US12509457B2 (en) Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2
WO2021084265A1 (en) Isoquinoline derivatives as sik2 inhibitors
HK40111483A (en) 2-quinolone derived inhibitors of bcl6
EP4584267A1 (en) Novel compounds as ck2 inhibitors
BR112019019358B1 (pt) Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230309

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250207

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250207

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250310

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250310

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250430

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250821

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250825